Workflow
Elanco(ELAN)
icon
Search documents
Elanco(ELAN) - 2024 Q3 - Earnings Call Transcript
2024-11-07 16:09
Elanco Animal Health Incorporated (NYSE:ELAN) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Katy Grissom - Head, Investor Relations Jeff Simmons - President & CEO Todd Young - EVP & CFO Conference Call Participants Michael Ryskin - Bank of America Merrill Lynch Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vazquez - William Blair Balaji Prasad - Barclays Chris Schott - JPMorgan Mike DiFiore - Evercore ISI David Westenberg - Piper Sandler Navann Ty - BNP Par ...
Compared to Estimates, Elanco Animal Health (ELAN) Q3 Earnings: A Look at Key Metrics
ZACKS· 2024-11-07 15:35
For the quarter ended September 2024, Elanco Animal Health Incorporated (ELAN) reported revenue of $1.03 billion, down 3.6% over the same period last year. EPS came in at $0.13, compared to $0.18 in the year-ago quarter.The reported revenue represents a surprise of -0.37% over the Zacks Consensus Estimate of $1.03 billion. With the consensus EPS estimate being $0.12, the EPS surprise was +8.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expec ...
INVESTOR REMINDER: Berger Montague Notifies Elanco Animal Health (NYSE: ELAN) Investors of a Class Action Lawsuit and Deadline
GlobeNewswire News Room· 2024-11-07 14:30
PHILADELPHIA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Elanco Animal Health Inc. (“Elanco” or the “Company”) (NYSE: ELAN). The lawsuit has been filed on behalf of purchasers of ELANCO securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”). CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT. Investors who purchased or acquired ELANCO securities during the Class Period may, no later than DECEMBER 6, 2024, seek to be appointed as a lead ...
Elanco(ELAN) - 2024 Q3 - Quarterly Report
2024-11-07 14:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, no par value ELAN New York Stock Exchange Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...
Elanco Animal Health Incorporated (ELAN) Q3 Earnings Top Estimates
ZACKS· 2024-11-07 13:35
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.33%. A quarter ago, it was expected that this company would post earnings of $0.24 per share when it actually produced earnings of $0.30, delivering a surprise of 25%.Over the last four quarters ...
Elanco(ELAN) - 2024 Q3 - Quarterly Results
2024-11-07 11:27
Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Third Quarter 2024 Results • Third Quarter 2024 Financial Results ◦ Revenue of $1,030 million, organic constant currency growth of 1% ◦ Reported Net Income of $364 million, Adjusted Net Income of $66 million ◦ Adjusted EBITD ...
Elanco Animal Health Reports Third Quarter 2024 Results
Prnewswire· 2024-11-07 11:27
Third Quarter 2024 Financial Results Revenue of $1,030 million, organic constant currency growth of 1% Reported Net Income of $364 million, Adjusted Net Income of $66 million Adjusted EBITDA of $163 million, or 15.8% of Revenue Reported EPS of $0.73, Adjusted EPS of $0.13 Net leverage ratio of 4.3x Adjusted EBITDA Pre-tax gain of $640 million from July 2024 divestiture of the aqua business Tightening full year 2024 financial guidance to reflect current assumptions: Revenue of $4,420 to $4,450 million, ...
The Gross Law Firm Reminds Elanco Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 6, 2024 - ELAN
Prnewswire· 2024-11-07 10:45
NEW YORK, Nov. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=110874&from=4CL ...
ELANCO ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Elanco Animal Health Incorporated and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2024-11-07 02:00
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Invest ...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 6, 2024 in Elanco Animal Health Incorporated Lawsuit – ELAN
GlobeNewswire News Room· 2024-11-06 18:17
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=110729& ...